KPV Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for KPV. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
KPV is discussed in experimental papers as the C-terminal tripeptide of alpha-MSH. The selected records use cell or animal models.
Questions covered by the selected literature
- How KPV was separated from other alpha-MSH sequences
- Which receptor and inflammation pathways were examined
- How delivery-system or wound models limit broader conclusions
Evidence limits
These studies do not establish general human-use outcomes. BioPep USA does not currently publish an active standalone KPV product page.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.. J Pharmacol Exp Ther. 2003 Aug. PMID: 12750433.
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.. Int J Physiol Pathophysiol Pharmacol. 2012. PMID: 22837805.
- Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide.. Exp Eye Res. 2006 Dec. PMID: 16965771.
BioPep USA record
BioPep USA does not currently publish an active standalone KPV product. The documentation page records that catalog status.
Last reviewed: July 20, 2026.
